Emerging safety issues regarding long-term usage of H(1)receptor antagonists (Q35194475)

7 August 2017

1 reference

title

Emerging safety issues regarding long-term usage of H(1)receptor antagonists (English)

1 reference

7 August 2017

Garry M Walsh

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

1

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

225-235

1 reference

Histaminergic systems and sleep. Studies in man with H1 and H2 antagonists.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Second-generation antihistamines in asthma therapy: is there a protective effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Molecular pharmacological aspects of histamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

New insights into the second generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Evaluation of loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Reversal of multidrug resistance by phenothiazines and structurally related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Pharmacological considerations in the modulation of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Loratadine and ventricular tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Antihistamines in late-phase clinical development for allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Clinical pharmacokinetics of mizolastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

The effects of terfenadine with and without alcohol on an aspect of car driving performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Sedative effects of antihistamines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Variations among non-sedating antihistamines: are there real differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

H1-receptor antagonists: safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Comparative tolerability of second generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Second-generation antihistamines: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

H1-receptor antagonist treatment of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Perennial allergic rhinitis: clinical efficacy of a new antihistamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Sleepiness and performance during three-day administration of cetirizine or diphenhydramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Psychometric aspects of antihistamines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Cardiotoxic effect with convulsions in terfenadine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Cardiac actions of antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Second-generation antihistamines: the risk of ventricular arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Loratadine produces antihistamine activity without adverse CNS, ECG or cardiovascular effects in guinea pigs. Comparative studies with terfenadine and sedating antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

A family of potassium channel genes related to eag in Drosophila and mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Desloratadine: A new, nonsedating, oral antihistamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Fexofenadine reduces nasal congestion in perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance: A Randomized, Placebo-Controlled Trial in the Iowa Driving Simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Safety of fexofenadine in children treated for seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

QT lengthening and life-threatening arrhythmias associated with fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

Considerations on third generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.225

21 January 2018

Identifiers

DOI

10.1517/14740338.1.3.225

1 reference

7 August 2017

1 reference